FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307640329> ?p ?o ?g. }

• W4307640329 endingPage "e005573" @default.
• W4307640329 startingPage "e005573" @default.
• W4307640329 abstract "Multiple PD-L1 immunohistochemistry (IHC) assays, including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1 IHC assays, have been approved by the Food and Drug Administration as a companion diagnostic (CDx) for various antiprogrammed death-1 and antiprogrammed death ligand 1 (PD-L1) based cancer immunotherapies. Here we present 22C3, 28-8, and SP142 analysis of 418 tumor specimens encountered in routine clinical practice.All specimens were tested with 22C3, 28-8, and SP142 assays following the manufacturer's established staining protocols.The same PD-L1 status (defined as tumor cell expression (TC) scores with all three assays ≥1% or all <1%) was observed in 60.0% (251/418) tumor specimens (45.9% (192/418) were triple negative and 14.1% (59/418) were triple positive). A total of 54.1% (226/418) tumor cases were positive with at least one IHC assay (94.2% (213/226), 77.0% (174/226), and 28.8% (65/226) of these were positive for 22C3, 28-8 and SP142, respectively). Among the 40.0% (167/418) tumor cases that showed a different PD-L1 status, 62.3% (104/167) were 22C3+/28-8+/SP142-, and 28.7% (48/167) were 22C3+/28-8-/SP142-. The same PD-L1 status with all three antibody clones was observed in 48.7% (97/199) of NSCLC cases, and among these, 54.6% (53/97) were triple negative and 45.4% (44/97) triple positive. A total of 73.4% (146/199) NSCLC cases were positive with at least one IHC assay (95.2% (n=139/146), 82.2% (n=120/146), and 32.2% (n=47/146) were positive for 22C3, 28-8, and SP142, respectively). Among the 51.3% (102/199) NSCLC cases that showed a different status among the three IHC assays, 67.6% (69/102) were 22C3+/28-8+/SP142-, and 23.5% (24/102) were 22C3+/28-8-/SP142-. A total of 81.1% (43/53) lung squamous cell carcinoma, 72.1% (88/122) of lung adenocarcinoma, 69.6% (16/23) of non-small cell lung cancer (NSCLC) not otherwise specified (NOS), and 50.0% (4/8) of small cell lung carcinoma cases were positive with at least one IHC assay.Our data suggest that 22C3 is the most sensitive PD-L1 IHC assay for tumor cell expression, followed by 28-8 and in turn by SP-142. These findings represent an additional factor for clinical teams to consider when deciding which PD-L1 IHC assay (and in turn which CDx-associated PD-L1 based immunotherapy) is most appropriate for each individual patient." @default.
• W4307640329 created "2022-11-04" @default.
• W4307640329 creator A5009875414 @default.
• W4307640329 creator A5025819053 @default.
• W4307640329 creator A5031047904 @default.
• W4307640329 creator A5034444686 @default.
• W4307640329 creator A5045665778 @default.
• W4307640329 creator A5064437499 @default.
• W4307640329 creator A5088559019 @default.
• W4307640329 date "2022-10-01" @default.
• W4307640329 modified "2023-10-01" @default.
• W4307640329 title "Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types" @default.
• W4307640329 cites W1568317937 @default.
• W4307640329 cites W1971208896 @default.
• W4307640329 cites W2010121426 @default.
• W4307640329 cites W2018968534 @default.
• W4307640329 cites W2058264985 @default.
• W4307640329 cites W2094723762 @default.
• W4307640329 cites W2124427232 @default.
• W4307640329 cites W2160834915 @default.
• W4307640329 cites W2161765043 @default.
• W4307640329 cites W2289712604 @default.
• W4307640329 cites W2293531514 @default.
• W4307640329 cites W2509467148 @default.
• W4307640329 cites W2529254901 @default.
• W4307640329 cites W2557730509 @default.
• W4307640329 cites W2560367415 @default.
• W4307640329 cites W2569740680 @default.
• W4307640329 cites W2582242752 @default.
• W4307640329 cites W2591568528 @default.
• W4307640329 cites W2740931940 @default.
• W4307640329 cites W2745683917 @default.
• W4307640329 cites W2747107882 @default.
• W4307640329 cites W2765696340 @default.
• W4307640329 cites W2769300445 @default.
• W4307640329 cites W2770260889 @default.
• W4307640329 cites W2804957255 @default.
• W4307640329 cites W2890298773 @default.
• W4307640329 cites W2892835911 @default.
• W4307640329 cites W2893960509 @default.
• W4307640329 cites W2897422388 @default.
• W4307640329 cites W2899927300 @default.
• W4307640329 cites W2906939357 @default.
• W4307640329 cites W2925815206 @default.
• W4307640329 cites W2974535149 @default.
• W4307640329 cites W2975441829 @default.
• W4307640329 cites W2988644538 @default.
• W4307640329 cites W2990398119 @default.
• W4307640329 cites W3001827637 @default.
• W4307640329 cites W3005186000 @default.
• W4307640329 cites W3022210979 @default.
• W4307640329 cites W3033185788 @default.
• W4307640329 cites W3037577284 @default.
• W4307640329 cites W3040196641 @default.
• W4307640329 cites W3099385733 @default.
• W4307640329 cites W3109717687 @default.
• W4307640329 cites W3158697155 @default.
• W4307640329 cites W3160377948 @default.
• W4307640329 cites W3167114692 @default.
• W4307640329 cites W3179558491 @default.
• W4307640329 cites W3192994113 @default.
• W4307640329 cites W4205814834 @default.
• W4307640329 cites W4224252326 @default.
• W4307640329 cites W4229033920 @default.
• W4307640329 doi "https://doi.org/10.1136/jitc-2022-005573" @default.
• W4307640329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36302564" @default.
• W4307640329 hasPublicationYear "2022" @default.
• W4307640329 type Work @default.
• W4307640329 citedByCount "8" @default.
• W4307640329 countsByYear W43076403292021 @default.
• W4307640329 countsByYear W43076403292023 @default.
• W4307640329 crossrefType "journal-article" @default.
• W4307640329 hasAuthorship W4307640329A5009875414 @default.
• W4307640329 hasAuthorship W4307640329A5025819053 @default.
• W4307640329 hasAuthorship W4307640329A5031047904 @default.
• W4307640329 hasAuthorship W4307640329A5034444686 @default.
• W4307640329 hasAuthorship W4307640329A5045665778 @default.
• W4307640329 hasAuthorship W4307640329A5064437499 @default.
• W4307640329 hasAuthorship W4307640329A5088559019 @default.
• W4307640329 hasBestOaLocation W43076403291 @default.
• W4307640329 hasConcept C121608353 @default.
• W4307640329 hasConcept C126322002 @default.
• W4307640329 hasConcept C142724271 @default.
• W4307640329 hasConcept C159654299 @default.
• W4307640329 hasConcept C203014093 @default.
• W4307640329 hasConcept C204232928 @default.
• W4307640329 hasConcept C2780416959 @default.
• W4307640329 hasConcept C71924100 @default.
• W4307640329 hasConcept C74864618 @default.
• W4307640329 hasConcept C86803240 @default.
• W4307640329 hasConceptScore W4307640329C121608353 @default.
• W4307640329 hasConceptScore W4307640329C126322002 @default.
• W4307640329 hasConceptScore W4307640329C142724271 @default.
• W4307640329 hasConceptScore W4307640329C159654299 @default.
• W4307640329 hasConceptScore W4307640329C203014093 @default.
• W4307640329 hasConceptScore W4307640329C204232928 @default.
• W4307640329 hasConceptScore W4307640329C2780416959 @default.
• W4307640329 hasConceptScore W4307640329C71924100 @default.

• next